Despite encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from PBMs. The organizations are frequently building obstacles to coverage, including steep cost criteria and approval processes that hinder user access. Industry suggest that these covera